Articles related to Psychiatry

In a phase 3 trial of 214 adults with generalized anxiety disorder, a single dose of DT120 orally disintegrating tablets produced greater reductions in anxiety scores than placebo through 12 weeks. Full peer-reviewed data and longer-term results remain pending.

A post hoc analysis of five brexpiprazole trials found improved functioning in adults with schizophrenia, including those with baseline hostility or agitation. The exploratory findings require interpretation alongside trial-design limitations and lack of multiplicity adjustment.

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.

A meta-analysis of seven studies found cannabinoid-based therapies were associated with lower agitation and neuropsychiatric symptom scores in patients with moderate to severe Alzheimer disease. Cognitive benefits were not consistently observed, and somnolence occurred more frequently with treatment.

A randomized crossover trial of 108 habitual cannabis users found fewer premature atrial contractions on cannabis-use days than abstinence days. The short-term physiologic findings provide mechanistic insight but were not designed to evaluate long-term cardiovascular health outcomes.

Among more than 7,300 Swedish patients with Alzheimer’s disease and atrial fibrillation, NOAC use was associated with slower cognitive decline than warfarin or no anticoagulation. The observational findings did not establish causality but suggest potential differences in long-term cognitive outcomes.